Treatment Lowers Testosterone Levels in Advanced Prostate Cancer Patients in Phase 3 Trial

Treatment Lowers Testosterone Levels in Advanced Prostate Cancer Patients in Phase 3 Trial
Foresee Pharmaceuticals has reported positive results from its Phase 3 clinical trial assessing FP-001 LMIS — a ready-to-use, testosterone-lowering treatment — in patients with advanced prostate cancer. Suppressing serum testosterone was the single-arm study's primary goal. The active agent in FP-001 LMIS, leuprolide mesylate, is a long-acting gonadotropin-releasing hormone (GnRH) agonist. Using GnRH agents for short periods can cause testosterone levels to rise, while sustained use is known to desensitize GnRH receptors and reduce testosterone production to castration levels. GnRH agonists that are on the market have complicated dosage forms and must be mixed right before they are used, Foresee 
Subscribe or to access all post and page content.